About Crosslink
Crosslink develops cancer treatments for people with solid tumors. Its technology uses a chemical found at much higher levels around tumors than normal tissue. That difference makes the treatments assemble inside tumors.
The company is based in Boston. Ron Seidel is its co-founder and CEO, and Rodolfo Chaparro is co-founder and scientific advisor. Both helped invent Crosslink's technology.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Oct 20, 2026 | $5,500,000fully sold | 8 | $687K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 17, 2025 | May 15, 2025 | $4,250,000of $8.0M target | 6 | $708K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $9,750,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Crosslink
The investment case centers on using tumor chemistry as a control switch for cancer drugs. Crosslink designed its system to assemble treatment where the target chemical is concentrated. That design could support multiple treatment formats. The intended result is better tumor targeting and greater activity.
The problem it targets
The target is extracellular adenosine triphosphate, or eATP, a molecule found outside cells. Solid tumors have much higher eATP levels than normal tissue. Tumors release it in large amounts to support their development and growth. Crosslink treats that concentration gap as a hallmark it can use for tumor-specific medicines.
What the product does
Crosslink engineered a modular biologic domain that uses the eATP difference to assemble therapies in tumors. Its first programs focus on drugs linked to antibodies and tumor-targeted radioactive treatments. These correspond to antibody-drug conjugates and radioligand therapies. Crosslink believes the same domain can work with many other treatment types.
Progress so far
Seidel and Chaparro previously co-founded Cue Biopharma and co-invented its technologies. Seidel served there as executive vice president and head of research and development. Chaparro was executive vice president and head of immunology, covering cancer immune therapy, autoimmune disease, and early development. Before Cue, both held research roles in biochemistry at Albert Einstein College of Medicine.
Who backs it
Cure Ventures includes Crosslink in its portfolio and describes it as a seed-stage oncology company. Cure co-founders and managing partners Dave Fallace and Lou Tartaglia serve as Crosslink directors.
We wrote this summary from public statements by Crosslink and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Crosslink's Form D filed Oct 20, 2026.
